Chemical and Pharmaceutical Bulletin p. 1458 - 1469 (1997)
Update date:2022-09-26
Topics:
Watanabe, Toshihiro
Kakefuda, Akio
Kinoyama, Isao
Takizawa, Kenji
Hirano, Seiko
Shibata, Hiroshi
Yanagisawa, Isao
A series of succinamide derivatives containing the 5,11-dihydro-6H- pyrido[2,3-b][1,4]benzodiazepin-6-one skeleton (6a-z) was prepared and evaluated for binding affinity to muscarinic receptors in vitro and for antagonism of bradycardia and salivation in vivo in comparison with AF-DX 116 (1a). Structure-activity relationships (SAR) studies in vitro indicated that the 4-(4-alkyl-1-piperazinyl)benzylamino moiety plays a crucial role in enhancing the infinity for M2 muscarinic receptors. Compound 6y, containing a 4-(4-isopropyl-1-piperazinyl)benzylmethylamino moiety, exhibited the highest affinity for M2 muscarinic receptors (pK(i) = 9.2), being 200 times as potent as 1a, and compound 6u, containing a 4-(4-ethyl-1- piperazinyl)benzylethylamino moiety, showed the highest selectivity for M2 over M3 muscarinic receptors (M3/M2 ratio=320). Both 6y and 6u antagonized the oxotremorine-induced bradycardia in rats after intravenous or oral administration. Oral evaluation in conscious dogs showed that the efficacy for increasing the heart rate was at least 3-fold greater than that of 1a.
View MoreGuangxi Shanyun Biochemical Science and Technology Co., Ltd
Contact:+86-0772--6828887
Address:#2 Industrial Park of Luzhai County, Liuzhou, Guangxi, China
Kaymossy BioChem Tech Co., Ltd
website:http://www.kaimosi.com
Contact:0571-87191913/0571-87199097
Address:Room 215, Building 3rd, No.288 Ningxia Road, Qingdao city, China
Contact:027-87677569
Address:Room 2203, yujingmingmen Buidling One, xiongchu Road, wuhan city, hubei province, China
MedicalChem(Yancheng)Manuf.Co.,Ltd.
Contact:+86-515-84383366
Address:Touzeng BinHai, YanCheng City, JiangSu Province, China
Xi'an Costrong Pharmaceutical Co., Ltd.
Contact:029- 68576496
Address:Room 2004,Shuibao Building,No.190,South Erhuan Rd, Yanta District,Xi'an,Shaan Xi,China
Doi:10.1021/jm501590q
(2015)Doi:10.1016/j.tetasy.2005.12.009
(2006)Doi:10.1021/ic0498081
(2004)Doi:10.1016/j.ica.2021.120606
(2021)Doi:10.1007/s11176-005-0265-3
(2005)Doi:10.1016/0022-2860(83)85073-X
(1983)